Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized Treatment for HBV-induced Compensated Liver Cirrhosis
NCT01943617Phase 4Completed
- Sponsor
- Beijing Friendship Hospital
- Start
- Jun 2013
- Primary completion
- Dec 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of thymosin alpha 1 in Liver cirrhosis (LC) and hepatitis B (HBV) (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Decompensated rate of Liver Cirrhosis at 2 years. Started Jun 2013; status: completed.
02
Drugs
thymosin alpha 1
03
Conditions
Liver cirrhosis (LC)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT01943617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01943617.